Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | BLM | P54132 | 3/20 | 0.41 |
| ▸ | NSD2 | O96028 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6667827 | 0.97 | TLR2 (0.42) | CYP19A1MEN1KMT2ABLMNSD2 | |
| SCHEMBL6664496 | 0.95 | CYP19A1 (0.41) | CYP19A1MEN1KMT2ABLMNSD2 | |
| SCHEMBL6663526 | 0.91 | CYP19A1 (0.42) | CYP19A1MEN1KMT2ABLMNSD2 | |
| SCHEMBL6662275 | 0.89 | MAPT (0.47) | MEN1KMT2ABLMNSD2POLB | |
| SCHEMBL6661989 | 0.89 | MAPT (0.47) | MEN1KMT2ABLMNSD2POLB | |
| SCHEMBL6665635 | 0.85 | MALT1 (0.45) | CYP19A1MEN1KMT2ABLMNSD2 | |
| SCHEMBL7111975 | 0.84 | TLR2 (0.39) | MEN1KMT2ABLMNSD2POLB | |
| SCHEMBL6661970 | 0.84 | NPC1 (0.46) | POLBNPC1RAB9AMTORSIRT2 | |
| SCHEMBL6664650 | 0.82 | MALT1 (0.44) | MEN1KMT2ABLMNSD2POLB | |
| SCHEMBL6659896 | 0.82 | MALT1 (0.44) | MEN1KMT2ABLMNSD2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | CYP19A1 1005/4885MEN1 3787/4885KMT2A 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.